Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin for Ischemic Neonatal Stroke
NCT03171818Phase 2Recruiting
- Start
- Jul 2017
- Primary completion
- Dec 2024
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in perinatal arterial ischemic stroke (PAIS) comparing Darbepoetin with Placebo (2 arms). Primary endpoint: Change in stroke tissue loss. Started Jul 2017; status: recruiting.
02
Drugs
darbepoetin alfa
03
Conditions
perinatal arterial ischemic stroke (PAIS)
Beyond the preview
Go deeper on NCT03171818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03171818.